These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 2433784

  • 21. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
    Noll G, Lämmle B, Duckert F.
    Thromb Haemost; 1984 Jul 29; 51(3):334-7. PubMed ID: 6238441
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D.
    J Cell Biochem; 1987 Feb 29; 33(2):77-86. PubMed ID: 3553213
    [Abstract] [Full Text] [Related]

  • 28. Prediction of deep vein thrombosis after extensive abdominal operations by the quotient between plasmin-alpha 2-antiplasmin complex and fibrinogen concentration in plasma.
    Mellbring G, Dahlgren S, Wiman B.
    Surg Gynecol Obstet; 1985 Oct 29; 161(4):339-42. PubMed ID: 2413560
    [Abstract] [Full Text] [Related]

  • 29. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR.
    Behring Inst Mitt; 1983 Aug 29; (73):43-55. PubMed ID: 6236789
    [Abstract] [Full Text] [Related]

  • 30. A unique pathway for the plasma elimination of alpha 2-antiplasmin-protease complexes in mice.
    Gonias SL, Fuchs HE, Pizzo SV.
    Thromb Haemost; 1982 Oct 29; 48(2):208-10. PubMed ID: 6758181
    [Abstract] [Full Text] [Related]

  • 31. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
    Grøndahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P, Danø K.
    J Lab Clin Med; 1988 Jan 29; 111(1):42-51. PubMed ID: 3121772
    [Abstract] [Full Text] [Related]

  • 32. Homogeneous immunoassay for alpha 2 plasmin inhibitor (alpha 2PI) and alpha 2PI-plasmin complex. Application of a sandwich liposome immune lysis assay (LILA) technique.
    Hosoda K, Yasuda T.
    J Immunol Methods; 1989 Jul 06; 121(1):121-8. PubMed ID: 2526837
    [Abstract] [Full Text] [Related]

  • 33. Fibrinolytic treatment by infusion of streptokinase-plasminogen-complex (activator): laboratory effects.
    Martin H, Auel H, Riedel C.
    Behring Inst Mitt; 1986 Feb 06; (79):263-71. PubMed ID: 2424424
    [Abstract] [Full Text] [Related]

  • 34. The suitability of various plasmin preparations for the functional assay of alpha 2-antiplasmin in plasma.
    Kluft C, Traas DW, Jie AF, Hoegee-de Nobel E.
    Thromb Haemost; 1982 Dec 27; 48(3):320-4. PubMed ID: 6219471
    [Abstract] [Full Text] [Related]

  • 35. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
    Du XH, Glas-Greenwalt P, Kant KS, Allen CM, Hayes S, Pollak VE.
    Clin Nephrol; 1985 Oct 27; 24(4):186-91. PubMed ID: 3933871
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.